Castle Biosciences, Inc. (CSTL)

Castle Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	344.23	332.07	219.79	137.04	94.09
Revenue Growth (YoY)	3.66%	51.09%	60.38%	45.65%	50.18%
Cost of Revenue	71.03	60.21	44.98	32.01	15.82
Gross Profit	273.2	271.86	174.81	105.03	78.26
Selling, General & Admin	229.32	200.05	180.15	143	86.74
Depreciation & Amortization Expenses	34.84	11.11	9.01	8.27	1.96
Research & Development	51.85	52.04	53.62	44.9	29.65
Other Operating Expenses	-	-	-	-18.29	-
Total Operating Expenses	316.01	263.19	242.78	177.89	118.34
Operating Income	-42.81	8.67	-67.98	-72.86	-40.08
Interest Income	13.24	13.47	10.62	3.97	0.07
Interest Expense	-0.09	-0.58	-0.01	-0.02	-0
Total Non-Operating Income (Expense)	13.15	12.89	10.61	3.95	0.07
Pretax Income	-29.66	21.56	-57.37	-68.9	-40.01
Provision for Income Taxes	-5.36	3.32	0.1	-1.77	8.72
Net Income	-24.3	18.25	-57.47	-67.14	-48.73
Net Income to Common	-24.3	18.25	-57.47	-67.14	-48.73
Shares Outstanding (Basic)	29	28	27	26	25
Shares Outstanding (Diluted)	29	29	27	26	25
Shares Change (YoY)	-0.92%	9.15%	2.87%	3.65%	32.80%
EPS (Basic)	-0.83	0.66	-2.14	-2.58	-1.24
EPS (Diluted)	-0.83	0.62	-2.14	-2.58	-1.24
Free Cash Flow	28.33	36.54	-19.25	-47.29	-22.47
Free Cash Flow Growth	-22.48%	-	-	-	-
Free Cash Flow Per Share	0.98	1.25	-0.72	-1.81	-0.89
Gross Margin	79.37%	81.87%	79.53%	76.64%	83.18%
Operating Margin	-12.44%	2.61%	-30.93%	-53.16%	-42.60%
Profit Margin	-7.06%	5.49%	-26.15%	-48.99%	-51.80%
FCF Margin	8.23%	11.00%	-8.76%	-34.51%	-23.88%
EBITDA	-2.04	24.67	-55.65	-62.31	-36.67
EBITDA Margin	-0.59%	7.43%	-25.32%	-45.47%	-38.98%
EBIT	-42.81	8.67	-67.98	-72.86	-40.08
EBIT Margin	-12.44%	2.61%	-30.93%	-53.16%	-42.60%
Effective Tax Rate	18.06%	15.39%	-0.18%	2.56%	-21.79%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q